Profit Margin (Quarterly) Chart

Historical Profit Margin (Quarterly) Data

View and export this data back to 2014. Start Trial.
Date Value
June 30, 2026 -584.5%
March 31, 2026 -821.6%
December 31, 2025 -488.0%
September 30, 2025 -477.3%
June 30, 2025 -503.9%
March 31, 2025 -598.7%
December 31, 2024 -283.3%
September 30, 2024 -236.6%
June 30, 2024 -266.3%
March 31, 2024 -438.9%
December 31, 2023 -197.4%
September 30, 2023 -3.42%
June 30, 2023 -136.2%
March 31, 2023 -226.7%
December 31, 2022 -110.4%
September 30, 2022 -202.2%
June 30, 2022 -153.0%
March 31, 2022 -95.11%
December 31, 2021 -31.28%
September 30, 2021 21.86%
June 30, 2021 -72.38%
March 31, 2021 42.51%
December 31, 2020 -1.16K%
September 30, 2020 -203.3%
June 30, 2020 -2.33K%
Date Value
March 31, 2020 -824.5%
December 31, 2019 -1.15K%
September 30, 2019 -2.27K%
June 30, 2019 -3.76K%
March 31, 2019 -3.48K%
December 31, 2018 -3.45K%
September 30, 2018 -3.01K%
June 30, 2018 -2.13K%
March 31, 2018 -4.05K%
December 31, 2017 -2.69K%
September 30, 2017 -2.98K%
June 30, 2017 -4.27K%
March 31, 2017 -3.37K%
December 31, 2016 -2.51K%
September 30, 2016 -2.01K%
June 30, 2016 -2.60K%
March 31, 2016 -2.37K%
December 31, 2015 -2.44K%
September 30, 2015 -2.69K%
June 30, 2015 -2.18K%
March 31, 2015 -1.78K%
December 31, 2014 -1.58K%
September 30, 2014 -5.10K%
June 30, 2014 -6.59K%
March 31, 2014 -25.98K%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
EyePoint, Inc. -18.63K%
ANI Pharmaceuticals, Inc. 8.65%
Theravance Biopharma, Inc. -28.45%
Corcept Therapeutics, Inc. 16.45%
Veru, Inc. --